Lantern Pharma's AI Platform Accelerates Precision Cancer Drug Development

Lantern Pharma's RADR AI platform is helping identify optimal indications and pathways for precision cancer therapies, potentially transforming the lengthy and costly process of oncology drug development. In oncology, the path from molecule discovery to patient treatment often stretches over a decade and can consume hundreds of millions of dollars, but artificial intelligence offers promising solutions to accelerate this timeline.

During a recent discussion titled "From Discovery to Clinical Trials to Patients: Key Decisions Shaping Novel CNS Oncology Medicines," Lantern CEO Panna Sharma and board member Dr. Lee Schalop explored how data-driven approaches can reshape cancer treatment development. Dr. Schalop reflected on lessons from developing ONC201, which was approved for H3K27M-mutant glioma after a 16-year journey, highlighting the potential for AI to significantly shorten such timelines.

Both leaders emphasized the potential for AI to accelerate regulatory reviews and clinical trial design, which could substantially reduce oncology drug development timelines and costs. This acceleration could improve patient access to new treatments by bringing effective therapies to market more quickly. Lantern Pharma, a clinical-stage biotechnology company leveraging artificial intelligence and machine learning, aims to challenge traditional development timelines through its innovative approaches.

The conversation underscored how AI-driven insights could benefit Lantern's new CNS cancer drug, STAR-001, by identifying optimal development pathways and potential indications. The company's approach represents a shift toward more efficient, data-driven drug development in the oncology space. For investors seeking the latest updates, information is available in the company's newsroom at https://ibn.fm/LTRN.

AINewsWire serves as a specialized communications platform focusing on artificial intelligence advancements and technologies driving innovation forward. As part of the Dynamic Brand Portfolio at IBN, the platform provides comprehensive distribution services including wire solutions, article syndication to 5,000+ outlets, and enhanced press release capabilities. Additional information about their services can be found at https://www.AINewsWire.com, with full terms of use and disclaimers available at https://www.AINewsWire.com/Disclaimer.